Retrospective Database Analysis to Explore Patterns and Economic Burden of Switchback to Brand After Generic or Authorized Generic Utilization
Justine Alderfer,1 Jyoti Aggarwal,2 Kim Gilchrist,1 Jose Maria Jimenez Alvir,3 Joseph Cook,4 Sang Hee Park,5 Jennifer M Stephens5 1Medical Affairs, Pfizer Inc., Collegeville, PA, USA; 2Evidence & Access, OPEN Health, Newton, MA, USA; 3Global Product Development, Pfizer Inc., New York, NY, USA; 4...
Saved in:
Main Authors: | Alderfer J (Author), Aggarwal J (Author), Gilchrist K (Author), Alvir JMJ (Author), Cook J (Author), Park SH (Author), Stephens JM (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2022-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Generic Drugs or Branded Generics, Which One You Prefer to Prescribe?
by: Manjunath Premanath, et al.
Published: (2024) -
ECONOMIC REASONS FOR GENERIC CHOICE
by: N. P. Kutishenko, et al.
Published: (2016) -
Evaluating the potential implications of canadian front-of-pack labelling regulations in generic and branded food composition databases
by: Christine Mulligan, et al.
Published: (2022) -
Physicochemical stability of three generic brands of metformin in solution
by: Radamés Alemón-Medina, et al.
Published: (2014) -
The concept of: Generic drugs and patented drugs Vs brand name drugs and non-proprietary (generic) name drugs.
by: Karan eThakkar, et al.
Published: (2013)